Market News AIOpen the app

ONC stock news · BeOne Medicines

Stories about BeOne Medicines (ONC) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for ONC

Follow BeOne Medicines (ONC) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ONC
Free on the App Store and Google Play, or on the web.
  1. Nov 16, 2026, 2:09 PM ET · Opinion

    Citizens analyst Reni J. Benjamin kept a positive rating on BeOne Medicines and raised the price target to $463.

    Good for ONC

    BeOne Medicines' analyst target rose from $405 to $463, and the analyst kept an Outperform rating. This favors BeOne's outlook, but reflects an analyst's view, not new company results.

  2. Sep 1, 2026, 5:06 AM ET · Deal

    Nine additional pharmaceutical partnerships announced by Trump increase total agreements to 26 — RFK Jr. shares insights on 'deeply emotional' discussions with the President.

    Bad for ONC

    BeOne Medicines is named among companies required to offer outpatient discounts, exposing it to lower U.S. pricing and revenue headwinds.